In its August 2019 network bulletin, UnitedHealthcare indicated that, beginning October 1, 2019, biosimilar bevacizumab (Mvasi) and biosimilar trastuzumab (Kanjinti), both made by Amgen, will be preferred products for commercial and community plans.
This article has been updated.
In its August 2019 network bulletin, UnitedHealthcare indicated that, beginning October 1, 2019, biosimilar bevacizumab (Mvasi) and biosimilar trastuzumab (Kanjinti), both made by Amgen, will be preferred products for commercial and community (but not Medicare Advantage) plans.
The reference bevacizumab (Avastin) and trastuzumab (Herceptin) will no longer be preferred products.
Additionally, other biosimilars, not yet launched in the United States, will not be preferred oncology products. In documents related to community plans, UnitedHealthcare indicated that Pfizer’s bevacizumab biosimilar (Zirabev), and trastuzumab biosimilars made by Celltrion and Teva (Herzuma), Mylan and Biocon (Ogivri), Samsung Bioepis (Ontruzant), and Pfizer (Trazimera) will be non-preferred products.
Other changes taking place on October 1 include listing biosimilar filgrastim (Zarxio), made by Sandoz, as a preferred product. Use of Zarxio will be required before use of follow-on filgrastim (Granix), brand-name filgrastim (Neupogen), or Pfizer’s biosimilar product (Nivestym).
Earlier this year, UnitedHealthcare announced that, in the case of pegfilgrastim, it would prefer Amgen’s brand-name pegfilgrastim, Neulasta, or Neulasta Onpro, a presentation of the pegfilgrastim product in an on-body injector device. Use of these products have, since July 1, been required before use of Mylan and Biocon’s biosimilar (Fulphila), or Coherus BioSciences’ biosimilar (Udenyca).
UnitedHealthcare also currently prefers other reference products to biosimilars; Brand-name infliximab (Remicade) is preferred over Celltrion and Pfizer’s biosimilar (Inflectra), and Samsung Bioepis and Merck’s biosimilar (Renflexis).
However, a representative from UnitedHealthcare previously told The Center for Biosimilars® in an email that, in October 2019 a change will take effect adding Inflectra to a preferred position along with Remicade. As such, beginning October 1, both Remicade and Inflectra will be preferred options for UnitedHealthcare commercial members.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.